Allogene Therapeutics Is A Clinical Stage Biotechnology Company Based In South San Franciscocaliforniafounded In 2018The Company Specializes In Developing Allogeneic Chimeric Antigen Receptor T Cellallocar Ta Ctherapies Aimed At Treating Cancer And Autoimmune Diseasesallogene S Innovativeoff The Shelfcar T Cell Platform Utilizes Donor Derived Cellswhich Enhances Accessibility And Scalability Compared To Traditional Patient Specific Therapies The Company S Pipeline Includes Several Investigational Candidates Targeting Various Malignanciesthese Include Allo 501 Allo 501A For Non Hodgkin Lymphomaallo 316 For Renal Cell Carcinomaallo 819 For Acute Myeloid Leukemiaallo 715 For Multiple Myelomaand Allo 605A Next Generation Car T Candidateallogene Also Employs Allo 647An Anti Cd52 Monoclonal Antibodyto Prepare Patients For Car T Infusionthe Company Focuses On Scalable Manufacturing Processes To Ensure Consistent Product Quality And Availabilityaddressing Challenges In The Production Of Autologous Car T Therapies
